Exagen, Medco Research Institute Aim to Improve Dosing Decisions for Rheumatoid Arthritis | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Specialty diagnostics laboratory Exagen and Medco Research Institute today announced they have begun a pilot program aimed at helping physicians make better dosing decisions for a rheumatoid arthritis medication.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.